Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
At the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Jyoti S. Mayadev, MD, a radiation oncologist and professor of radiation medicine and applied sciences at the University of California, San Diego School of Medicine, spoke with CancerNetwork® about where future research efforts are likely to be focused within the cervical cancer space. In particular, Mayadev highlighted how combination immunotherapies and biomarker research will be areas of focus for this population.
We've seen that immunotherapy with cervical cancer has been efficacious and improved survival in the metastatic setting. There have been synergies with various checkpoint inhibitors, including dual checkpoint inhibition—tyrosine kinase inhibitors [TKIs] and immunotherapy synergy. There have been new developments in terms of LAG-3 [inhibitors]. We have a real opportunity with novel therapeutics in cervical cancer and combinations with immunotherapy and synergies that will be better elucidated with biomarker development and better prediction tools as to which patients will unfortunately succumb to their disease despite standard therapy. Those are the patients that we need to enrich our clinical trial patient population with.